Overview

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada

Status:
No longer available
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages of 3-16 who are failing or intolerant of their current antiretroviral regimen and who are unable to swallow Sustiva capsules.
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Efavirenz